{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:50:39Z","timestamp":1773683439356,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,3,25]],"date-time":"2011-03-25T00:00:00Z","timestamp":1301011200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s11864-011-0148-2","type":"journal-article","created":{"date-parts":[[2011,3,24]],"date-time":"2011-03-24T04:06:45Z","timestamp":1300939605000},"page":"136-148","source":"Crossref","is-referenced-by-count":39,"title":["New Treatment Options for Patients with Advanced Neuroendocrine Tumors"],"prefix":"10.1007","volume":"12","author":[{"given":"Jennifer A.","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew H.","family":"Kulke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,3,25]]},"reference":[{"issue":"18","key":"148_CR1","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, et al. One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063\u201372.","journal-title":"J Clin Oncol"},{"issue":"1","key":"148_CR2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1055-3207(02)00076-5","volume":"12","author":"JM Sarmiento","year":"2003","unstructured":"Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am. 2003;12(1):231\u201342.","journal-title":"Surg Oncol Clin N Am"},{"issue":"4","key":"148_CR3","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1245\/ASO.2006.03.071","volume":"13","author":"DA Osborne","year":"2006","unstructured":"Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13(4):572\u201381.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"148_CR4","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/01.sla.0000161981.58631.ab","volume":"241","author":"JG Touzios","year":"2005","unstructured":"Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241(5):776\u201383. discussion 783\u20135.","journal-title":"Ann Surg"},{"issue":"6","key":"148_CR5","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.surg.2006.07.033","volume":"140","author":"B Givi","year":"2006","unstructured":"Givi B, Pommier SJ, Thompson AK, et al. Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery. 2006;140(6):891\u20137. discussion 897\u20138.","journal-title":"Surgery"},{"key":"148_CR6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00000658-199704000-00002","volume":"225","author":"H Lang","year":"1997","unstructured":"Lang H, Oldhafer K, Weimann A, et al. Liver transplantation for metastatic neuroendocrine tumors. Ann Surg. 1997;225:347\u201354.","journal-title":"Ann Surg"},{"issue":"4","key":"148_CR7","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00000658-199704000-00003","volume":"225","author":"YP Treut Le","year":"1997","unstructured":"Le Treut YP, Delpero JR, Dousset B, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg. 1997;225(4):355\u201364.","journal-title":"Ann Surg"},{"key":"148_CR8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00130404-200307000-00008","volume":"9","author":"S Gupta","year":"2003","unstructured":"Gupta S, Yao J, Ahrar K, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the MD Anderson experience. Cancer J. 2003;9:261\u20137.","journal-title":"Cancer J"},{"issue":"5","key":"148_CR9","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.2214\/ajr.180.5.1801379","volume":"180","author":"C Loewe","year":"2003","unstructured":"Loewe C, Schindl M, Cejna M, et al. Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR Am J Roentgenol. 2003;180(5):1379\u201384.","journal-title":"AJR Am J Roentgenol"},{"key":"148_CR10","doi-asserted-by":"crossref","first-page":"302","DOI":"10.7326\/0003-4819-120-4-199402150-00008","volume":"120","author":"C Moertel","year":"1994","unstructured":"Moertel C, Johnson C, McKusick M, et al. The management of patients with advanced carcinoid tumors and islet cell carcinoma. Ann Int Med. 1994;120:302\u20139.","journal-title":"Ann Int Med"},{"issue":"3","key":"148_CR11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/COC.0b013e31815e4557","volume":"31","author":"AS Kennedy","year":"2008","unstructured":"Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31(3):271\u20139.","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"148_CR12","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/cncr.23685","volume":"113","author":"J King","year":"2008","unstructured":"King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008;113(5):921\u20139.","journal-title":"Cancer"},{"key":"148_CR13","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1196\/annals.1294.026","volume":"1014","author":"EP Krenning","year":"2004","unstructured":"Krenning EP, Kwekkeboom DJ, Valkema R, et al. Peptide receptor radionuclide therapy. Ann NY Acad Sci. 2004;1014:234\u201345.","journal-title":"Ann NY Acad Sci"},{"issue":"9","key":"148_CR14","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s002590100502","volume":"28","author":"WA Breeman","year":"2001","unstructured":"Breeman WA, de Jong M, Kwekkeboom DJ, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med. 2001;28(9):1421\u20139.","journal-title":"Eur J Nucl Med"},{"issue":"4","key":"148_CR15","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.bpg.2005.04.001","volume":"19","author":"JJ Teunissen","year":"2005","unstructured":"Teunissen JJ, Kwekkeboom DJ, de Jong M, et al. Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol. 2005;19(4):595\u2013616.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"10","key":"148_CR16","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2009.22.8585","volume":"28","author":"DL Bushnell Jr","year":"2010","unstructured":"Bushnell Jr DL, O\u2019Dorisio TM, O\u2019Dorisio MS, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010;28(10):1652\u20139.","journal-title":"J Clin Oncol"},{"issue":"13","key":"148_CR17","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","volume":"26","author":"DJ Kwekkeboom","year":"2008","unstructured":"Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124\u201330.","journal-title":"J Clin Oncol"},{"key":"148_CR18","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","volume":"17","author":"J Rubin","year":"1999","unstructured":"Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17:600\u20136.","journal-title":"J Clin Oncol"},{"key":"148_CR19","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM198609113151102","volume":"315","author":"L Kvols","year":"1986","unstructured":"Kvols L, Moertel C, O\u2019Connell M, et al. Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analog. N Engl J Med. 1986;315:663\u201366.","journal-title":"N Engl J Med"},{"key":"148_CR20","doi-asserted-by":"crossref","unstructured":"O\u2019Toole D, Ducreux M, Bommelaer G, et al., Treatment of carcinoid syndrome: A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000; 88(770).","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0"},{"issue":"Suppl 1","key":"148_CR21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000080741","volume":"80","author":"HA Schmid","year":"2004","unstructured":"Schmid HA, Schoeffter P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology. 2004;80 Suppl 1:47\u201350.","journal-title":"Neuroendocrinology"},{"key":"148_CR22","doi-asserted-by":"crossref","unstructured":"Kvols L, Wiedenmann B, Oberg K, et al. Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a phase II study. JCO, 2006. ASCO Annual Meeting(4082).","DOI":"10.1200\/jco.2006.24.18_suppl.4082"},{"issue":"28","key":"148_CR23","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656\u201363.","journal-title":"J Clin Oncol"},{"key":"148_CR24","doi-asserted-by":"crossref","unstructured":"Frank M, Klose K, Wied M et al. Combination therapy with octreotide and alpha-interferon: Effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol. 1999;94(1381).","DOI":"10.1016\/S0002-9270(99)00146-X"},{"key":"148_CR25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/02841869309083916","volume":"32","author":"E Janson","year":"1993","unstructured":"Janson E, Oberg K. Long term management of the carcinoid syndrome: treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol. 1993;32:225\u20139.","journal-title":"Acta Oncol"},{"key":"148_CR26","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3109\/02841869109092411","volume":"30","author":"K Oberg","year":"1991","unstructured":"Oberg K, Eriksson B. The role of interferons in the management of carcinoid tumors. Acta Oncol. 1991;30:519\u201322.","journal-title":"Acta Oncol"},{"issue":"22","key":"148_CR27","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1200\/JCO.2005.03.616","volume":"23","author":"W Sun","year":"2005","unstructured":"Sun W, Lipsitz S, Catalano P, et al. Phase II\/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol. 2005;23(22):4897\u2013904.","journal-title":"J Clin Oncol"},{"key":"148_CR28","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM199202203260804","volume":"326","author":"C Moertel","year":"1992","unstructured":"Moertel C, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, stretpozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519\u201323.","journal-title":"N Engl J Med"},{"key":"148_CR29","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1200\/JCO.2004.04.024","volume":"22","author":"M Kouvaraki","year":"2004","unstructured":"Kouvaraki M, Ajani J, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004;22:4762\u201371.","journal-title":"J Clin Oncol"},{"issue":"22","key":"148_CR30","first-page":"5846","volume":"47","author":"MF Stevens","year":"1987","unstructured":"Stevens MF, Hickman JA, Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987;47(22):5846\u201352.","journal-title":"Cancer Res"},{"issue":"10","key":"148_CR31","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-06-2053","volume":"13","author":"S Ekeblad","year":"2007","unstructured":"Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007;13(10):2986\u201391.","journal-title":"Clin Cancer Res"},{"key":"148_CR32","unstructured":"Kulke M, Blaszkowsky L, Zhu A et al. Phase I\/II study of everolimus (RAD001) in combination with temozolomide (TMZ) in patients (pts) with advanced pancreatic neuroendocrine tumors (NET). 2010 Gastrointestinal Cancers Symposium, 2010: p. Abstract 127."},{"key":"148_CR33","doi-asserted-by":"crossref","unstructured":"Kulke M, Stuart K, Earle C et al. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings 2006;24(18S):Abstract 4044.","DOI":"10.1200\/jco.2006.24.18_suppl.4044"},{"issue":"1","key":"148_CR34","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-08-1476","volume":"15","author":"MH Kulke","year":"2009","unstructured":"Kulke MH, Hornick JL, Frauenhoffer C, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009;15(1):338\u201345.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"148_CR35","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","volume":"24","author":"MH Kulke","year":"2006","unstructured":"Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006;24(3):401\u20136.","journal-title":"J Clin Oncol"},{"key":"148_CR36","doi-asserted-by":"crossref","unstructured":"Strosberg JR, Fine RL, Choi J et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2010 [Epub ahead of print].","DOI":"10.1002\/cncr.25425"},{"issue":"8","key":"148_CR37","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2007.13.6374","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008;26(8):1316\u201323.","journal-title":"J Clin Oncol"},{"key":"148_CR38","doi-asserted-by":"crossref","unstructured":"Hobday TJ, Rubin J, Holen K et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I, 2007;25(18S):Abstract 4504.","DOI":"10.1200\/jco.2007.25.18_suppl.4504"},{"key":"148_CR39","doi-asserted-by":"crossref","unstructured":"Phan A, Yao J, Fogelman D et al. A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). Journal of Clinical Oncology, 2010 ASCO Annual Meeting Proceedings 2010;28(15S):Abstract 4044.","DOI":"10.1200\/jco.2010.28.15_suppl.4001"},{"issue":"20","key":"148_CR40","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1200\/JCO.2007.15.9020","volume":"26","author":"MH Kulke","year":"2008","unstructured":"Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26(20):3403\u201310.","journal-title":"J Clin Oncol"},{"key":"148_CR41","unstructured":"Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501\u201313. This randomized, phase III study demonstrated an improvement in progression-free survival for patients with advanced pancreatic neuroendocrine tumor receiving sunitinib compared to placebo."},{"issue":"4","key":"148_CR42","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/annonc\/mdi113","volume":"16","author":"S Vignot","year":"2005","unstructured":"Vignot S, Faivre S, Aguirre D, et al. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol. 2005;16(4):525\u201337.","journal-title":"Ann Oncol"},{"issue":"18","key":"148_CR43","doi-asserted-by":"crossref","first-page":"10320","DOI":"10.1073\/pnas.171060098","volume":"98","author":"K Podsypanina","year":"2001","unstructured":"Podsypanina K, Lee RT, Politis C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70\/S6 kinase activity in Pten+\/\u2212 mice. Proc Natl Acad Sci USA. 2001;98(18):10320\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"148_CR44","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00022744-200206000-00008","volume":"10","author":"L Wang","year":"2002","unstructured":"Wang L, Ignat A, Axiotis CA. Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Appl Immunohistochem Mol Morphol. 2002;10(2):139\u201346.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"9","key":"148_CR45","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/sj.bjc.6603419","volume":"95","author":"I Duran","year":"2006","unstructured":"Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer. 2006;95(9):1148\u201354.","journal-title":"Br J Cancer"},{"issue":"26","key":"148_CR46","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2008.16.7858","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008;26(26):4311\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"148_CR47","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","volume":"28","author":"JC Yao","year":"2010","unstructured":"Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28(1):69\u201376.","journal-title":"J Clin Oncol"},{"key":"148_CR48","unstructured":"Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514\u201323. The RADIANT-3 trial, a randomized, phase III study, demonstrated an improvement in progression-free survival for patients with advanced pancreatic neuroendocrine tumor receiving the mTOR inhibitor everolimus compared to placebo."},{"key":"148_CR49","unstructured":"Yao J, Phan A, Fogleman D et al. Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. J Clin Oncol. 2010;28:15s, (suppl; abstr 4002) 2010."},{"key":"148_CR50","doi-asserted-by":"crossref","unstructured":"Chan J, Mayer R, Jackson N et al. Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors (NET). J Clin Oncol. 2010;28(suppl; abstr e14597) 2010.","DOI":"10.1200\/jco.2010.28.15_suppl.e14597"},{"key":"148_CR51","doi-asserted-by":"crossref","unstructured":"Chan J, Ryan D, Fuchs C et al. Phase I study of pasireotide (SOM230) in combination with everolimus (RAD001) in patients (pts) with advanced neuroendocrine tumors (NET) in Gastrointestinal Cancers Symposium 2010; Orlando.","DOI":"10.1200\/jco.2011.29.15_suppl.4120"},{"key":"148_CR52","doi-asserted-by":"crossref","unstructured":"Yao J, NG C, Hoff P et al. Improved progression-free survival and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab (abstract). J Clin Oncol. 2005;23(309s).","DOI":"10.1200\/jco.2005.23.16_suppl.4007"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-011-0148-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-011-0148-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-011-0148-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T14:40:35Z","timestamp":1592404835000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-011-0148-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,25]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["148"],"URL":"https:\/\/doi.org\/10.1007\/s11864-011-0148-2","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,25]]}}}